<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03387020</url>
  </required_header>
  <id_info>
    <org_study_id>PBTC-050</org_study_id>
    <secondary_id>NCI-2017-02079</secondary_id>
    <secondary_id>PBTC-050</secondary_id>
    <secondary_id>PBTC-050</secondary_id>
    <secondary_id>UM1CA081457</secondary_id>
    <nct_id>NCT03387020</nct_id>
  </id_info>
  <brief_title>Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors</brief_title>
  <official_title>A Phase I and Surgical Study of Ribociclib and Everolimus (RAD001) in Children With Recurrent or Refractory Malignant Brain Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pediatric Brain Tumor Consortium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Pediatric Brain Tumor Consortium</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies the side effects and best dose of ribociclib and everolimus and to
      see how well they work in treating patients with malignant brain tumors that have come back
      or do not respond to treatment. Ribociclib may stop the growth of tumor cells by blocking
      some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as everolimus,
      work in different ways to stop the growth of tumor cells, either by killing the cells, by
      stopping them from dividing, or by stopping them from spreading. Giving ribociclib and
      everolimus may work better at treating malignant brain tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To estimate the maximum tolerated dose (MTD) and/or the recommended phase II dose (RP2D)
      of ribociclib and everolimus in children with refractory or recurrent central nervous system
      (CNS) tumors. (Phase I) II. To describe the toxicity profile and define the dose-limiting
      toxicities (DLTs) of ribociclib and everolimus in children with refractory or recurrent CNS
      tumors. (Phase I) III. To characterize the pharmacokinetics of ribociclib and everolimus in
      children with refractory or recurrent CNS tumors, and the potential for drug-drug
      interactions between the two compounds in this population. (Phase I) IV. To characterize
      ribociclib concentrations in tumor, and plasma in children with refractory or recurrent CNS
      malignancies undergoing neurosurgical procedures. (Surgical Study)

      SECONDARY OBJECTIVES:

      I. To describe the response rate of relapsed and refractory malignant brain tumors to
      ribociclib and everolimus in the context of a phase I study. (Phase I) II. To explore the
      effect of ribociclib treatment on Ki-67 by immunohistochemistry (IHC) by comparing archival
      and post-treatment tumor tissue. (Surgical Study)

      TERTIARY OBJECTIVES:

      I. To increase knowledge of the genomic landscape of treatment-refractory pediatric CNS
      tumors, including mechanisms of resistance and response.

      OUTLINE: This is a dose-escalation study.

      Patients receive ribociclib orally (PO) once daily (QD) on days 1-21 of course 1 and
      subsequent courses and days 2-21 of course 2, and everolimus PO QD on days 3-28 of course 1
      and days 1-28 of subsequent courses. Patients who are undergoing surgery also receive
      ribociclib PO QD on days 7-10 before surgery. Treatment repeats every 28 days for up to 13
      courses in the absence of disease progression or unacceptable toxicity. Patients with stable
      disease after 13 courses may continue receiving ribociclib and everolimus every 28 days for
      up to 13 additional courses in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up at 30 days.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 13, 2018</start_date>
  <completion_date type="Anticipated">July 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of ribociclib and everolimus</measure>
    <time_frame>4 weeks</time_frame>
    <description>Defined as the highest dose level at which six patients have been treated with at most one patient experiencing a dose limiting toxicity (DLT) and the next higher dose level has been determined to be too toxic. Will be estimated using a Rolling-6 phase I design. Will summarize DLTs observed on the study by dose level and by attribution in a table format.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Average Tumor and Plasma Concentrations of Ribociclib for the Surgical Study</measure>
    <time_frame>Surgical study: Prior to starting ribociclib (day -7 or -10), prior to ribociclib dose on days -5 &amp; -2, day 0, and at the time of surgery</time_frame>
    <description>Average tumor Ribociclib concentrations will be compared to plasma concentrations and described descriptively.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective responses (complete response + partial response)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be described by dose and by histology. Prolonged stable diseases will also be reported in a descriptive fashion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent reduction in ki67 between archival and post-treatment tissue</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>For the Surgical Study, Ki67 will be evaluated in paired pre-treatment tumor (diagnostic) and post-treatment tumor (recurrent) tissue in consenting patients to assess reduction</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Ribociclib AUC (Area under the plasma concentration versus time curve) as obtained from the Phase 1 Study</measure>
    <time_frame>Pre-dose, 1, 2, 4, 8, 24, 32 (day 1 course 1 only), &amp; 48 (day 1 course 1 only) hours after dose on days 1 and 17 of course 1.</time_frame>
    <description>Ribociclib plasma concentration-time data obtained from the Phase 1 Study will be modeled using compartmental approaches to estimate the AUC (ng/ml*hr).</description>
  </other_outcome>
  <other_outcome>
    <measure>Everolimus AUC (Area under the plasma concentration versus time curve)</measure>
    <time_frame>Pre-dose, 0.5 (course 2 only), 1, 1.5 (course 2 only), 2, 4, 6 (course 2 only), 8, 24 hours after dose on day 17 of course 1, and day 1 of course 2.</time_frame>
    <description>Everolimus plasma concentration-time data obtained from the Phase 1 Study will be modeled using compartmental approaches to estimate the AUC (ng/ml*hr).</description>
  </other_outcome>
  <other_outcome>
    <measure>Ribociclib Half-Life as obtained from the Phase 1 Study</measure>
    <time_frame>Pre-dose, 1, 2, 4, 8, 24, 32 (day 1 course 1 only), &amp; 48 (day 1 course 1 only) hours after dose on days 1 and 17 of course 1.</time_frame>
    <description>Ribociclib plasma concentration-time data obtained from the Phase 1 Study will be modeled using compartmental approaches to estimate its half-life (hrs).</description>
  </other_outcome>
  <other_outcome>
    <measure>Everolimus Half Life as obtained from the Phase 1 Study</measure>
    <time_frame>Pre-dose, 0.5 (course 2 only), 1, 1.5 (course 2 only), 2, 4, 6 (course 2 only), 8, &amp; 24 hours after dose on day 17 of course 1, and day 1 of course 2</time_frame>
    <description>Everolimus plasma concentration-time data obtained from the Phase 1 Study will be modeled using compartmental approaches to estimate its half-life (hrs).</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Central Nervous System Embryonal Tumor, Not Otherwise Specified</condition>
  <condition>Malignant Glioma</condition>
  <condition>Recurrent Atypical Teratoid/Rhabdoid Tumor</condition>
  <condition>Recurrent Childhood Ependymoma</condition>
  <condition>Recurrent Diffuse Intrinsic Pontine Glioma</condition>
  <condition>Recurrent Medulloblastoma</condition>
  <condition>Refractory Diffuse Intrinsic Pontine Glioma</condition>
  <arm_group>
    <arm_group_label>Treatment (ribociclib, everolimus)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive ribociclib PO QD on days 1-21 of course 1 and subsequent courses and days 2-21 of course 2, and everolimus PO QD on days 3-28 of course 1 and days 1-28 of subsequent courses. Patients who are undergoing surgery also receive ribociclib PO QD on days 7-10 before surgery. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity. Patients with stable disease after 13 courses may continue receiving ribociclib and everolimus every 28 days for up to 13 additional courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (ribociclib, everolimus)</arm_group_label>
    <other_name>42-O-(2-Hydroxy)ethyl Rapamycin</other_name>
    <other_name>Afinitor</other_name>
    <other_name>Certican</other_name>
    <other_name>RAD 001</other_name>
    <other_name>RAD001</other_name>
    <other_name>Votubia</other_name>
    <other_name>Zortress</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (ribociclib, everolimus)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (ribociclib, everolimus)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribociclib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (ribociclib, everolimus)</arm_group_label>
    <other_name>Kisqali</other_name>
    <other_name>LEE-011</other_name>
    <other_name>LEE011</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ELIGIBILITY FOR SCREENING

          -  Patients with a histologically confirmed diagnosis of high-grade glioma (HGG),
             medulloblastoma, CNS embryonal tumor (not otherwise specified [NOS]), ependymoma, or
             atypical teratoid rhabdoid tumor (ATRT) that is recurrent, progressive or refractory

          -  Patients with recurrent diffuse intrinsic pontine glioma (DIPG) with typical
             radiographic appearance who have undergone biopsy are eligible provided there is
             histologic confirmation of malignant glioma World Health Organization (WHO) II-IV; Rb1
             screening for these patients is required only if adequate tissue is available

          -  Patients with recurrent brainstem tumors with an atypical presentation who have
             undergone biopsy are eligible provided there is histologic confirmation of malignant
             glioma WHO II-IV; these patients must undergo Rb1 screening; these patients must have
             radiographic evidence of progression

          -  Patients with secondary malignant gliomas will be eligible for this study but should
             conform to all other eligibility requirements; patients with low-grade gliomas are
             excluded

          -  Formalin fixed paraffin embedded tumor tissue (preferably from the most recent
             recurrence) must be available to assess Rb1 protein status prior to enrollment on
             phase I or surgical study; if the subject has results from prior Rb1 IHC testing in a
             Clinical Laboratory Improvement Act (CLIA)-certified laboratory the requirement for
             screening to assess Rb1 protein status is waived

          -  Patients with recurrent diffuse intrinsic brain stem glioma (DIPG) that has an
             atypical presentation must also submit the tumor tissue for Rb1 protein status
             confirmation or provide previous testing results from a CLIA certified laboratory;
             patients who have been biopsied for atypical DIPG but do not have sufficient tissue
             for Rb1 screening are not eligible

          -  Body surface area (BSA)

               -  Patients enrolled on dose level -1 must have BSA &gt;= 0.55m^2

               -  Patients enrolled on dose level -0.5 must have BSA &gt;= 0.75m^2

               -  Patients enrolled on dose level 0 must have BSA &gt;= 0.55m^2

               -  Patients enrolled on dose level 1 must have BSA &gt;= 0.75m^2

               -  Patients enrolled on dose level 2 and 3 must have BSA &gt;= 0.45m^2

          -  Patients who are candidates for enrollment for the phase I or surgical studies must
             sign a screening consent and provide pre-trial tumor material for Rb1 testing unless
             testing is not needed due to diagnosis or the availability of prior Rb1 IHC results;
             the screening consent is to be obtained according to institutional guidelines

          -  Patients screened for this trial should be expected to meet the criteria for treatment

          -  PRIOR TO STUDY ENROLLMENT

          -  PHASE I (STRATUM 1): Patient has intact Rb1 protein confirmed either from previous
             results or screened tissue; all testing must be performed in a CLIA certified
             laboratory; DIPG patients with radiographically typical appearance will be waived from
             this requirement

          -  PHASE I (STRATUM 1): Patients with a histologically confirmed diagnosis of a primary
             CNS tumor that is recurrent, progressive, or refractory; all tumors must have
             histologic verification of HGG, medulloblastoma, CNS embryonal tumor (NOS),
             ependymoma, or ATRT; patients with low-grade gliomas are excluded

          -  PHASE I (STRATUM 1): Patients with progressive DIPG, as defined by progressive
             neurologic abnormalities or worsening neurologic status not explained by causes
             unrelated to tumor progression (e.g., anticonvulsant or corticosteroid toxicity wean,
             electrolyte disturbances, sepsis, hyperglycemia, etc.), OR an increase in the
             bi-dimensional measurement, taking as a reference the smallest disease measurement
             recorded since last treatment, OR the appearance of a new tumor lesion since diagnosis

               -  Please note:

                    -  Patients with a radiographically typical DIPG, defined as a tumor with a
                       pontine epicenter and diffuse involvement of more than 2/3 of the pons, are
                       eligible without histologic confirmation

                    -  Patients with pontine lesions that do not meet these radiographic criteria
                       will be eligible if there is histologic confirmation of malignant glioma WHO
                       II-IV. These patients must have radiographic evidence of progression

          -  SURGICAL STUDY (STRATUM 2): Patients must have recurrent or refractory disease with a
             histological diagnosis at either the time of diagnosis or at the time of recurrence of
             one of the following:

               -  HGG

               -  Medulloblastoma,

               -  CNS embryonal tumor (NOS),

               -  Ependymoma, or

               -  ATRT

          -  SURGICAL STUDY (STRATUM 2): Patients for whom surgical intervention is clinically
             indicated (gross total resection or sub-total resection) at recurrence and are
             amenable to receiving ribociclib for 7 ? 10 days prior to resection

               -  Note: patients with DIPG are excluded from the surgical study

          -  BSA

               -  Patients enrolled on dose level -1 must have BSA &gt;= 0.55m2

               -  Patients enrolled on dose level -0.5 must have BSA &gt;= 0.75m2

               -  Patients enrolled on dose level 0 must have BSA &gt;= 0.55m2

               -  Patients enrolled on dose level 1 must have BSA &gt;= 0.75m2

               -  Patients enrolled on dose level 2 and 3 must have BSA &gt;= 0.45m2

          -  Patients must have received prior therapy other than surgery and must have fully
             recovered from the acute toxic effects of all prior anti-cancer therapy and must meet
             the following minimum duration from prior anti-cancer directed therapy prior to
             enrollment

          -  Patients must have received their last dose of known myelosuppressive anticancer
             therapy at least 21 days prior to enrollment or at least 42 days if nitrosourea

          -  Biologic or investigational agent (anti-neoplastic): patient must have recovered from
             any acute toxicity potentially related to the agent and received their last dose of
             the investigational or biologic agent &gt;= 7 days prior to study enrollment

               -  For agents that have known adverse events occurring beyond 7 days after
                  administration, this period must be extended beyond the time during which adverse
                  events are known to occur

          -  Monoclonal antibody treatment and agents with known prolonged half-lives: At least
             three half-lives must have elapsed prior to enrollment.

          -  Patients must have had their last fraction of:

               -  Craniospinal irradiation (&gt; 24 GRAY [Gy]) or total body irradiation &gt; 12 weeks
                  prior to enrollment

               -  Focal irradiation &gt; 2 weeks prior to enrollment

               -  &gt;= 3 months since autologous bone marrow/stem cell transplant prior to enrollment

          -  Neurologic status

               -  Patients with neurological deficits should have deficits that are stable for a
                  minimum of 1 week prior to enrollment

               -  Patients with seizure disorders may be enrolled if seizures are well controlled
                  on an anti-epileptic drug that is not a strong inducer or inhibitor of CYP3A4/5
                  are eligible

          -  Performance status

               -  Phase I: Karnofsky performance scale (KPS for &gt; 16 years of age) or Lansky
                  performance score (LPS for =&lt; 16 years of age) assessed within one week of
                  enrollment must be &gt;= 50

               -  Surgical study: Karnofsky performance scale (KPS for &gt; 16 years of age) or Lansky
                  performance score (LPS for =&lt; 16 years of age) assessed within one week of
                  enrollment must be &gt;= 60

               -  Patients who are unable to walk because of neurologic deficits, but who are up in
                  a wheelchair, will be considered ambulatory for the purpose of assessing the
                  performance score

          -  Absolute neutrophil count &gt;= 1.0 x 10^9 cells/ L

          -  * Platelets &gt;= 100 x 10^9 cells/ L (unsupported, defined as no platelet transfusion
             within 7 days)

          -  Hemoglobin &gt;= 8g/dl (unsupported)

          -  Total bilirubin =&lt; 1.5 times institutional upper limit of normal (ULN)

          -  Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =&lt; 3 x
             institutional upper limit of normal (ULN)

          -  Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) =&lt; 3
             x institutional upper limit of normal (ULN)

          -  Albumin &gt;= 2 g/dl

          -  Serum creatinine based on age/gender; patients that do not meet the criteria but have
             a 24 hour creatinine clearance or glomerular filtration rate (GFR) (radioisotope or
             iothalamate) &gt;= 70 mL/min/1.73 m^2 are eligible

          -  Patients who are receiving dexamethasone must be on a stable or decreasing dose for at
             least 1 week prior to enrollment

          -  Patients must be off all colony- forming growth factor(s) for at least 1 week prior to
             enrollment (i.e. filgrastim, sargramostim or erythropoietin); 2 weeks must have
             elapsed if patients received long-acting formulations

          -  Female patients of childbearing potential must have a negative serum or urine
             pregnancy test

          -  Patients of childbearing or child fathering potential must be willing to use a
             medically acceptable form of birth control while being treated on this study; Highly
             effective contraception methods include:

               -  Total abstinence when this is in line with the preferred and usual lifestyle of
                  the patient; periodic abstinence (e.g., calendar, ovulation, symptothermal,
                  post-ovulation methods) and withdrawal are not acceptable methods of
                  contraception

               -  Combination of any of the two following

                    -  Use of oral, injected or implanted hormonal methods of contraception or
                       other forms of hormonal contraception that have comparable efficacy (failure
                       rate &lt; 1%), for example hormone vaginal ring or transdermal hormone
                       contraception

                    -  Placement of an intrauterine device (IUD) or intrauterine system (IUS)

                    -  Barrier methods of contraception: condom or occlusive cap (diaphragm or
                       cervical/vault caps) with spermicidal foam/gel/film/cream/ vaginal
                       suppository

               -  Note: oral contraceptives are allowed but should be used in conjunction with a
                  barrier method of contraception due to unknown effect of drug-drug interaction;
                  in case of use of oral contraception, women should have been stable on the same
                  pill for a minimum of 3 months before taking study treatment

          -  Female patients must agree not to breastfeed their infants while on study; patients of
             child fathering potential (defined as &gt; Tanner stage 2) must use a condom during
             intercourse while taking the drug during treatment, for 8 weeks after stopping
             treatment and should not father a child in this period; a condom is required to be
             used also by vasectomized men during intercourse with a male or female partner in
             order to prevent delivery of the study drug via semen

          -  The patient or parent/guardian is able to understand the consent and is willing to
             sign a written informed consent document according to institutional guidelines;
             assent, when appropriate, will be obtained according to institutional guidelines

        Exclusion Criteria:

          -  Patients who are otherwise deemed clinically unsuitable for surgical resection
             (applicable for surgical study only)

          -  Patients who are breast feeding

          -  Patients with any clinically significant unrelated systemic illness (serious
             infections or significant cardiac, pulmonary, hepatic or other organ dysfunction),
             that would compromise the patient?s ability to tolerate protocol therapy, put them at
             additional risk for toxicity or would interfere with the study procedures or results

          -  Patients who are receiving any other anticancer or investigational or/and
             anti-neoplastic therapies, including chemotherapy, immunotherapy, target therapy,
             biological response modifiers

               -  Previous treatment with CDK4/6 inhibitors (such as PD-0332991, abemaciclib)
                  and/or mTOR inhibitors (such as sirolimus, temsirolimus or everolimus)

               -  Patients who are currently receiving treatment with agents that are known to
                  cause corrected QT (QTc) prolongation or induce Torsades de Pointes

               -  Known need for major surgery within 14 days of the first dose of ribociclib and
                  everolimus; please note: gastrostomy, insertion of a gastrostomy (G) tube,
                  ventriculo-peritoneal shunt, endoscopic ventriculostomy and central venous access
                  are NOT considered major surgery

          -  Patient is currently receiving any of the following medications and cannot be
             discontinued 7 days prior to enrollment:

               -  Known strong and moderate inducers or inhibitors of CYP3A4/5, including enzyme
                  inducing anti-convulsant drugs (EIACDs), grapefruit, grapefruit hybrids,
                  pummelos, star-fruit, and Seville oranges

               -  Substrates of CYP3A4/5 with a narrow therapeutic index

               -  Herbal preparations/medications (except for vitamins) including, but not limited
                  to: St. John?s wort, Kava, ephedra (ma huang), gingko biloba,
                  dehydroepiandrosterone (DHEA), yohimbe, saw palmetto, black cohosh and ginseng;
                  patients should stop using all herbal medications and dietary supplements at
                  least 7 days prior to enrollment

          -  Clinically significant active cardiac disease, uncontrolled heart disease and/or a
             history of cardiac dysfunction including any of the following:

               -  History of acute coronary syndromes (including myocardial infarction, unstable
                  angina, coronary artery bypass grafting, coronary angioplasty, or stenting) or
                  symptomatic pericarditis within 12 months prior to screening

               -  History of documented congestive heart failure (New York Heart Association
                  functional classification III-IV)

               -  Documented cardiomyopathy

               -  Patient has a left ventricular ejection fraction (LVEF) &lt; 50% as determined by
                  echocardiogram (ECHO)

               -  History of any cardiac arrhythmias, e.g., ventricular, supraventricular, nodal
                  arrhythmias, or conduction abnormality within 12 months of screening

               -  Long QT syndrome or known family history of idiopathic sudden death or congenital
                  long QT syndrome, or any of the following:

                    -  Risk factors for Torsades de Pointe (TdP) including uncorrected hypokalemia
                       or hypomagnesemia, history of cardiac failure, or history of clinically
                       significant/symptomatic bradycardia

                    -  Concomitant use of medication(s) with a known risk to prolong the QT
                       interval and/or days prior to starting study drug) or replaced by safe
                       alternative medication

               -  12-lead electrocardiogram (ECG), any of the following cardiac parameters:

                    -  QTc &gt; 480 msec

               -  Hypertension defined as:

                    -  Patients 1-17 years of age with blood pressure that is greater than or equal
                       to the 95th percentile for age, height and gender at the time of enrollment;
                       Patients who are â‰¥ 18 years of age with blood pressure &gt; 140/90 mm of Hg at
                       the time of enrollment.

          -  Patient is currently receiving warfarin or other coumadin-derived anticoagulant for
             treatment, prophylaxis or otherwise.

          -  Patient has a known hypersensitivity to ribociclib or any of its excipients

          -  Patients with inability to return for required follow-up visits or obtain follow-up
             studies required to assess toxicity to therapy or to adhere to drug administration
             plan, other study procedures, and study restrictions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mariko DeWire, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pediatric Brain Tumor Consortium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stacye Richardson, MSHS</last_name>
    <phone>901-595-3783</phone>
    <email>stacye.richardson@stjude.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emily Carps, MBA</last_name>
    <phone>901-595-5762</phone>
    <email>emily.carps@stjude.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90026</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Girish Dhall, MD</last_name>
      <phone>323-361-4629</phone>
      <email>gdhall@chla.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Girish Dhall, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lucile Packard Children Hospital Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michelle Monje</last_name>
      <phone>650-721-5750</phone>
      <email>mmonje@stanford.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kathleen Dorris</last_name>
      <phone>720-777-1234</phone>
      <email>kathleen.dorris@childrenscolorado.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eugene Hwang, M.D.</last_name>
      <phone>202-476-5046</phone>
      <email>ehwang@childrensnational.org</email>
    </contact>
    <contact_backup>
      <last_name>Sabrina Malik</last_name>
      <phone>202-476-5115</phone>
      <email>smalik@childrensnational.org</email>
    </contact_backup>
    <investigator>
      <last_name>Eugene Hwang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tobey MacDonald</last_name>
      <phone>404-727-1447</phone>
      <email>tobey.macdonald@emory.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute Pediatric Oncology Branch</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kathlerine E. Warren</last_name>
      <phone>301-435-4683</phone>
      <email>warrenk@mail.nih.gov</email>
    </contact>
    <investigator>
      <last_name>Kathlerine E. Warren</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ira Dunkel</last_name>
      <phone>212-639-2153</phone>
      <email>dunkeli@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Ira Dunkel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maryam Fouladi</last_name>
      <phone>513-803-0721</phone>
      <email>maryam.fouladi@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Maryam Fouladi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ian Pollack</last_name>
      <phone>412-692-5881</phone>
      <email>Pollaci@chp.edu</email>
    </contact>
    <investigator>
      <last_name>Ian Pollack, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pediatric Brain Tumor Consortium</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mariko D. DeWire</last_name>
      <phone>513-636-4266</phone>
      <email>mariko.dewire@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Mariko D. DeWire</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Jude Children Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giles Robinson, MD</last_name>
      <phone>901-595-2907</phone>
      <email>giles.robinson@stjude.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Children's Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patricia Baxter, MD</last_name>
      <phone>832-824-4681</phone>
      <email>pabaxter@txch.org</email>
    </contact>
    <contact_backup>
      <last_name>Susan Burlingame, CCRP</last_name>
      <phone>832-824-1532</phone>
      <email>sxburlin@txch.org</email>
    </contact_backup>
    <investigator>
      <last_name>Patricia Baxter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2017</study_first_submitted>
  <study_first_submitted_qc>December 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 29, 2017</study_first_posted>
  <last_update_submitted>March 9, 2018</last_update_submitted>
  <last_update_submitted_qc>March 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Ependymoma</mesh_term>
    <mesh_term>Medulloblastoma</mesh_term>
    <mesh_term>Rhabdoid Tumor</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

